BioNanoSim
Improved Versions of Existing Drugs and Cannabis Delivery
Company Overview
Snapshot
Founded in July 2015 by Simon Benita, BioNanoSim operates with 1–10 employees. The company has raised $6 million across one funding round. In January 2016, BioNanoSim entered into an exclusive worldwide licensing and development agreement with Immune Pharmaceuticals for a novel topical nano-capsule formulation of cyclosporine.
Business overview
BioNanoSim (BNS) is a Health Tech & Life Sciences company focused on drug delivery. It has developed a proprietary technology platform for the nano-encapsulation of drugs, aiming to enhance delivery profiles and therapeutic performance. The company's research demonstrates the potential of its nano-encapsulation technology across various therapeutic areas, including oncology, ophthalmology, and metabolic diseases. Additionally, BNS applies its nano-encapsulation technologies to develop topical and ocular cannabis-based products, serving the pharmaceuticals and medical cannabis markets.
Strategic signal
In January 2016, BioNanoSim secured an exclusive worldwide licensing and development agreement with Immune Pharmaceuticals for a novel topical nano-capsule formulation of cyclosporine. This partnership validates BioNanoSim's nano-encapsulation technology and provides a strategic pathway for the development of new treatments for chronic inflammatory skin disorders, signaling strong commercial potential and external recognition of its innovative drug delivery platform.
Log in to access full profile ›Company Intelligence Q&A
- What is BioNanoSim's core technology?
- BioNanoSim has developed a proprietary technology platform for the nano-encapsulation of drugs to improve their delivery profile and therapeutic performance.
- Which therapeutic areas does BioNanoSim's technology address?
- BioNanoSim's nano-encapsulation technology has demonstrated potential across various therapeutic areas, including oncology, ophthalmology, and metabolic diseases.
- What significant partnership did BioNanoSim establish in early 2016?
- In January 2016, BioNanoSim entered into an exclusive worldwide licensing and development agreement with Immune Pharmaceuticals for a novel topical nano-capsule formulation of cyclosporine.
- What types of cannabis-based products does BioNanoSim develop?
- BioNanoSim uses its nano-encapsulation technologies to develop topical and ocular cannabis-based products.
- Who is the founder of BioNanoSim?
- BioNanoSim was founded by Simon Benita in July 2015.